anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:A compound expressed by formula I (R1 is H or lower alkyl; R2 is H, lower alkyl or acyl which may be substituted by halogen; R3 is halogen, lower alkyl or lower alkoxy) and salt thereof. EXAMPLE:cis-3-Acetylaminomethyl-4-chloropyrrolidine. USE:An intermediate for producing pyridonecarboxylic acid derivatives having antimicrobial activity. PREPARATION:A compound expressed by formula II (Z is -CH2N3 or -CN) or formula III (R'2 is acyl group) is reduced in the presence of a reducing agent, e.g. Pd-C or Raney Ni, in a solvent, e.g. THF or methanol, at 0-80 deg.C for 30 min-24hr while stirring. If R is a protecting group, it is removed from the resultant reaction product to afford the aimed compound expressed by formula I.
BACKGROUND: Health-related quality of life (HRQoL) assessments and estimates of prognosis are needed for comprehensive care and planning of subsequent treatment in patients with idiopathic pulmonary fibrosis (IPF). We investigated HRQoL and its association with survival using a disease-specific tool in patients with IPF.
METHODS: The patients were recruited from the real-life FinnishIPF study in 2015. HRQoL was assessed with the King's Brief Interstitial Lung Disease (K-BILD) questionnaire every six months for 2.5 years. Dyspnoea was assessed with the modified Medical Research Council (mMRC) dyspnoea scale. Survival was registered until 31 December 2022. Patient survival according to the K-BILD total score was evaluated using the Kaplan‒Meier method. The Friedman test was used to compare the K-BILD total scores longitudinally, and the Mann‒Whitney U test was used to compare the mMRC groups. P values < 0.05 were considered statistically significant.
RESULTS: The median K-BILD total score (n = 245) was 51.6. At baseline, patients in the highest HRQoL quartile (K-BILD scores 58.9-100) had a longer median survival time (5.3 years) than did those with scores of 51.7-58.8 (3.1 years), 45.7-51.6 (2.3 years), and 0.0-45.6 (1.8 years). A decrease in the K-BILD total score of ≥ 5 units in the preceding 12 or 24 months showed a trend towards poorer survival, although statistical significance was not reached. Ninety-four patients survived more than 2.5 years and had available K-BILD data at all time points. The K-BILD total score remained higher in patients with a baseline mMRC of 0-1 than in those with a mMRC of 2-4, and the total score decreased only modestly in both groups (median of 3.3 and 4.8 units in patients with mMRC scores of 0-1 and 2-4, respectively).
CONCLUSIONS: In IPF, a reduced HRQoL is associated with impaired survival. A K-BILD total score less than approximately 50 units is associated with a median survival of approximately two years. In addition to assessing the treatment needs of patients with IPF using K-BILD, a decreased score may be useful for facilitating advance care planning and transplantation assessment.
PURPOSE:To obtain a cosmetic containing uniformly dispersed components, having clear color, giving excellent make-up and having excellent spreadability and applicability to the skin, by compounding gypsum dihydrate with a coloring composition composed of inorganic pigment, organic pigment, dye, natural pigment, etc. CONSTITUTION:25-99.9pts. of gypsum containing 0-0.5mol of water as water of crystallization per one molecule is uniformly mixed with 0.1-75pts. of one or more kinds of substances selected from inorganic pigment, organic pigment, dye and natural pigment. The mixture is added with 25-150pts. of water or an aqueous solvent solution and stirred to obtain a uniform dispersion, which is left standing for 3-24hr at room temperature. The dispersion is dried at 40-80 deg.C and crushed. The obtained colorant composition is compounded in an amount of 1-60wt% to obtain the objective cosmetic. The above colorant composition exhibits excellent dispersibility when compounded in a cosmetic base, gives clear color tone, is free from color mottling and gives a coated color which can be easily matched with the apparent color.
The problem of the increasing obesity among children and adolescents is urgent. One of the most interesting and promising directions in this area is to study the correlation of individual microorganisms with the presence and absence of obesity. The aim of the study was to assess the correlation between the isolation frequency of individual microorganisms and the presence of obesity in children and adolescents and to identify possible associations between different groups of microorganisms in obese patients. Material and methods. 156 male and female patients aged from 7 to 17 years were included in the study. The patients were divided into a control group (n=23) (healthy patients), a group of children with exogenous constitutional obesity without complications (n=25), a group of children who had one or more complications of obesity (n=108). For all patients body mass index (BMI) was calculated. Additional examination included a cultural study of the intestinal microbiota. Fecal samples of patients were used as the material. Preparation of the material for inoculation, inoculation and subsequent incubation of the Petri plates were carried out under anaerobic conditions. The isolated microorganisms were identified using the MALDI-ToF mass spectrometry method. Results. When analyzing the correlation between obesity and individual taxa, statistically significant differences were obtained only for Bifidobacterium spp. (p=0.045). The analysis of the correlation between obesity and the isolation of individual microorganisms has shown that Bifidobacterium pseudocatenulatum (p=0.012), Candida albicans (p=0.012), Streptococcus salivarius (p=0.016), Bifidobacterium breve (p=0.003), Veillonella parvula (p=0.013), Haemophilus parainfluenzae (p=0.003), Streptococcus oralis (p=0.001), Weissella confusa (p=0.036), Enterococcus mundtii (p=0.036) were isolated less often in patients with obesity than in control group. Conclusion. The results of the study has demonstrated that only one taxon, Bifidobacterium spp., had a significant correlation with the absence of obesity. At the same time, a reliable correlation with the absence of obesity was also established for individual microorganisms, including several microorganisms from Bifidobacterium spp. and Streptococcus spp., which may enable to establish certain microbiological predictors of obesity and its complications.
The recommended dose of Neulasta is two doses, 6 mg each, administered subcutaneously one week apart. For dosing in pediatric patients weighing less than 45 kg, refer to Table 1. Administer the first dose as soon as possible after suspected or confirmed exposure to radiation levels greater than 2 gray (Gy). Administer the second dose one week after the first dose. 

Obtain a baseline complete blood count (CBC). Do not delay administration of Neulasta if a CBC is not readily available. Estimate a patient's absorbed radiation dose (i.e., level of radiation exposure) based on information from public health authorities, biodosimetry if available, or clinical findings such as time to onset of vomiting or lymphocyte depletion kinetics.
This is a randomized (individuals will be assigned in a random order to study treatment sequences), open-label (identity of assigned treatment sequences will be known), single dose, 2-cycle, crossover (patients will receive both treatments in a random order) bioequivalence study of DOXIL/CAELYX (doxorubicin HCL) in patients with advanced or refractory solid malignancies (including patients with ovarian cancer). This study has an adaptive 2-stage design. Bioequivalence based on encapsulated doxorubicin will be tested at the end of Stage 1 using data from at least 24 ovarian cancer patients. An interim analysis of free doxorubicin will be performed at the end of Stage 1 using data from 42 patients of all cancer types. The study may continue into Stage 2 with additional patients of all cancer types; and final evaluation of bioequivalence for free doxorubicin will be performed at the end of Stage 2. The study will include a screening phase followed by an open-label treatment phase consisting of 2 doxorubicin treatment cycles and an end-of-treatment visit on Cycle 3, Day 1. Participants may enter an optional extension phase after 2 cycles. Safety will be monitored throughout the study. Blood samples for pharmacokinetic analysis will be obtained from all participants at specified times over 29 days after starting each study drug administration in Cycles 1 and 2 for determination of plasma concentrations of encapsulated and free doxorubicin.
OBJECTIVE: This research aims to explore the efficiency and safety of endoscopic combined intrarenal surgery (Micro-ECIRS) composed of micro-percutaneous nephrolithotomy (Micro-perc) and retrograde intrarenal surgery (RIRS) in the Galdakao-modified supine Valdivia (GMSV) position for a single session for the treatment of complex nephrolithiasis in children.
MATERIALS AND METHODS: This study retrospectively reviewed patients aged < 18 years who underwent Micro-ECIRS in the GMSV position for renal stones larger than 2 cm under ultrasound guidance between August 2020 to May 2022 at our institution.
RESULTS: A total of 13 patients (8 males and 5 females) received Micro-ECIRS for renal stones under ultrasound guidancewhile adopting the GMSV position. The average stone size was 2.7 cm (range: 2.1-3.7 cm). Among them, 6 patients had left kidney stones, 5 patients had right kidney stones, and 2 patients had bilateral kidney stones. The mean operative time was 70.5 min (range: 54-93 min). The mean hospital stay was 6.4 days (range: 4-9 days). The mean hemoglobin decrease was 8.2 g/L (range: 5.1-12.4 g/L). The total number of kidneys that had complete stone clearance was 8 kidneys at 48 h postoperatively, 11 kidneys at 2 weeks postoperatively, and 14 kidneys at 1 month postoperatively.
CONCLUSION: Our results demonstrate that Micro-ECIRS while patients are in the GMSV position is a safe and effective method for the treatment of complex children nephrolithiasis. However, all children made three hospital visits and received anesthesia three times. Further research is needed to confirm these findings.
NEW MATERIAL:N-(alpha-Fluoro-4-methylcinnamoyl)phenylalanine expressed by the formula and a salt thereof. USE:An absorption promoter capable of imparting absorbability to a polypeptide based pharmaceutical, e.g. insulin, enhancing the absorbability and exhibiting high activity in a small dose with very high safety. PREPARATION:L-Phenylalanine is reacted with alpha-fluoro-4-methylcinnamoyl chloride in a solvent, e.g. acetone, in the presence of sodium hydroxide to afford the compound expressed by formula I. The above-mentioned compound is used in an amount of 0.1-2,000mg. preferably 0.2-500mg based on 25 units medicines, e.g. insulin, and administered in 0.1-1,000mg does per patient divided several times in 0.2-2,000mg total daily dose.
INTRODUCTION: Peritoneal dialysis (PD) is an effective renal replacement modality in people with HIV (PWH) with end-stage kidney disease (ESKD), particularly those with residual kidney function. Data on pharmacokinetics (PK) of antiretrovirals in patients on peritoneal dialysis are limited.
METHODS: A single-participant study was performed on a 49-year-old gentleman with ESKD on PD and controlled HIV on once daily dolutegravir (DTG) 50 mg + tenofovir alafenamide (TAF) 25 mg / emtricitabine (FTC) 200 mg. He underwent serial blood plasma, peripheral blood mononuclear cell, and urine PK measurements over 24 h after an observed DTG + FTC/TAF dose.
RESULTS: Plasma trough (Cmin) concentrations of TAF, tenofovir (TFV), FTC, and DTG were 0.05, 164, 1,006, and 718 ng/mL, respectively. Intracellular trough concentrations of TFV-DP and FTC-TP were 1142 and 11,201 fmol/million cells, respectively. Compared to published mean trough concentrations in PWH with normal kidney function, observed TFV and FTC trough concentrations were 15.5- and 20-fold higher, while intracellular trough concentrations of TFV-DP and FTC-TP were 2.2-fold and 5.4-fold higher, respectively. TFV and FTC urine levels were 20 times lower than in people with normal GFR.
CONCLUSIONS: In a single ESKD PWH on PD, daily TAF was associated with plasma TFV and intracellular TFV-DP trough concentrations 15-fold and 2-fold higher than those of people with uncompromised kidney function, potentially contributing to nephrotoxicity. This suggests that TFV accumulates on PD; thus, daily TAF in PD patients may require dose adjustment or regimen change to optimize treatment, minimize toxicity, and preserve residual kidney function.
The invention discloses a method for processing gastrodia elata bl. original-shape slices, wherein the method comprises the following steps: washing gastrodia elata bl. cleanly, placing the gastrodia elata bl. in a normal pressure steamer, and carrying out water-insulation steaming at the temperature of 80-90 DEG C for 30-45 min until the gastrodia elata bl. is done for enzyme deactivation; placing the gastrodia elata bl. after enzyme deactivation in a drying oven, and carrying out first-stage drying; slicing the gastrodia elata bl. after drying by a dislocated opposite cutting method comprising the steps of dividing the gastrodia elata bl. after drying into an upper part and a lower part with the central axis as a boundary, slicing the upper part with the slice thickness of 2-3 mm, cutting until reaching the central axis, then slicing the lower part with the slice thickness still of 2-3 mm, cutting until reaching the central axis in the same way, but allowing the lower knife edge to be staggered with the upper knife edge, and thus obtaining the gastrodia elata bl. slices connected with each other; allowing the gastrodia elata bl. slices to stand, and carrying out first-stage back sweating; and after the first-stage back sweating is finished, respectively drying for 4 times, and carrying out back sweating for 3 times, to obtain the dried product. The method can ensures that the dried gastrodia elata bl. product is convenient to eat, the original shape of the gastrodia elata bl. can be kept, the hardness of the gastrodia elata bl. is reduced, standards are easy to control, and the method can be widely popularized.
FIELD: medicine. SUBSTANCE: means is prepared from celandine herb. It contains celandine herb extract and base stuff taken in 2 to 3 proportion with respect to dry herb mass. Natural fat and synthesized fat-like substances or gum or gum mixtures or cotton or cellulose or its derivatives are taken as the base stuff. The means is prepared by producing celandine herb extract done at room temperature to the extractant boiling point during 5 h to 10 days depending on extraction mode when mass proportion of extractant/dry herb mass varies from 4/1 to 6/1. The so produced extract is mixed with the base stuff taken in 2:3 proportion with respect to the dry herb mass. EFFECT: high antibacterial activity; alleviated tooth ache. 3 cl
In patients with acute circulatory failure, it is recommended to assess fluid responsiveness. Fluid responsiveness is defined by an increase in cardiac output of 10 to 15% after fluid loading. The assessment of fluid responsiveness usually needs cardiac output monitoring (or stroke volume). However, in limited resource settings or during the initial management of patients with acute circulatory failure, cardiac output measurement is usually unavailable. The perfusion index (PI) is derived from the plethysmographic signal of the pulse oximeter and represents the ratio between the ratio of pulsatile on non-pulsatile light absorbance of the plethysmography signal. The PI is influenced by vascular and stroke volume. The investigators hypothesized that the peripheral index could track the changes in cardiac output induced by fluid loading and therefore detect fluid responsiveness.

Adult patients with acute circulatory failure in whom physicians want to test the fluid responsiveness will be included. At baseline, the PI will be recorded. An initial echocardiography will be performed to measure the left ventricular outflow tract velocity time integral (a surrogate of stroke volume). A fluid loading with 500 ml of 0.9% Saline or Ringer Lactate will be performed. After fluid administration, the velocity time integral and the PI will be collected. Fluid-responsive patients are defined by a 15% increase in velocity time integral. The investigators will analyze the ability of the PI to detect fluid responsiveness.
Cerebellar damage causes the disabling movement disorder ataxia, which is characterized by impaired movement coordination affecting all body movements. In the arms, ataxia causes reaching movements with irregular, oscillating, and prolonged trajectory paths. People with cerebellar ataxia (PWCA) are also impaired in an important form of motor learning, called adaptation, which normally keeps movement well calibrated. In prior research, the principal investigator showed that PWCA can learn to correct their reaching movements if they instead employ reinforcement learning (RL). Although many PWCA learned optimally in RL conditions, this prior work found variability across individuals: some learned more than others. While adaptation critically relies on cerebellar integrity, RL depends more heavily on dopaminergic circuitry in the midbrain and excitatory plasticity in M1. Cerebellar damage has been shown to increase intracortical inhibition in M1, which may hamper the plasticity needed for RL. The repetitive TMS protocols of continuous theta burst stimulation (cTBS) and intermittent theta burst stimulation (iTBS) have further been shown to modulate intracortical inhibition: cTBS decreases it, while iTBS increases it. Here, the investigators will systematically test whether increased intracortical inhibition in M1 predicts RL capacity (Aim 1) and whether modulating inhibition in M1 can alter RL capacity in PWCA (Aim 2). 12 PWCA from a degenerative condition will complete 4 experimental sessions over a 6-month period. In session 1, TMS will be used to assess baseline recruitment curves for corticomotor excitability and short-interval intracortical inhibition, and the cortical silent period. PWCA will then complete a standardized clinical rating of their ataxia severity and an established behavioral task that requires learning a reaching skill using the RL paradigm. In sessions 2-4, PWCA will complete 3 additional sessions of the RL task. In each session, PWCA will receive cTBS, iTBS, or sham stimulation to modulate intracortical inhibition in M1 prior to performing the RL task. For Aim 1, the investigators will use multi-level regression to quantify relationships between TMS measures of M1 state and the magnitude and speed of learning in the RL task. For Aim 2, the investigators will use multi-level modeling to quantify differences in the magnitude and speed of learning across stimulation conditions. The investigators hypothesize that increased baseline inhibition in M1 will show a positive association with a lower magnitude and speed of learning in the RL task (Aim 1), and cTBS will improve the magnitude of learning, the speed of learning, or both, in the RL task relative to iTBS or sham stimulation (Aim 2).
BOTOX Cosmetic (onabotulinumtoxinA) for injection, is a sterile, vacuum-dried purified botulinum toxin type A, produced from fermentation of Hall strain Clostridium botulinum type A intended for intramuscular use. It is purified from the culture solution by dialysis and a series of acid precipitations to a complex consisting of the neurotoxin, and several accessory proteins. The complex is dissolved in sterile sodium chloride solution containing Albumin Human and is sterile filtered (0.2 microns) prior to filling and vacuum-drying.
Elevated body mass index (BMI) is linked to increased pancreatic cancer (PC) risk. Cancer-associated weight loss can occur years before the malignancy is diagnosed. This might have led to underestimation of the BMI-PC association. However, it is unknown if and to what extent this issue has been considered in previous epidemiological studies. We searched two databases through February 19, 2024 for systematic reviews, meta-analyses, and pooled analyses examining the BMI-PC association. We extracted information on study design with a special focus on the article's examination of prediagnostic weight loss as a potential source of bias, as well as how included cohort studies addressed this concern. Thirteen review articles, meta-analyses, and pooled analyses were identified. Only five (four pooled analyses, one systematic review) considered prediagnostic weight loss in their analyses. Twenty-four of 32 identified cohort studies reported having excluded initial years of follow-up. However, only 13 studies reported results after such exclusions, and effect estimates generally increased with longer periods of exclusion. We conclude that the association of overweight and obesity with PC risk is likely larger than suggested by published epidemiological evidence. Future studies should pay careful attention to avoid or minimize potential bias resulting from prediagnostic weight loss.
Patients receive fluorouracil IV, epirubicin IV over 15 minutes, and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses.
Subjects will receive a single dose inhalation of GSK2269557 200 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
Ischemic stroke is characterized by high morbidity and mortality and a lack of effective therapeutic interventions. Leptin plays an important role in regulating oxidative stress, angiogenesis, hematopoiesis, etc. Although recent studies have found a neuroprotective effect of leptin, little is known about its role in cerebral ischemia. This study explores the possible roles and potential preventative mechanisms of leptin in cerebral ischemia-reperfusion injury (CIRI). An in vivo middle cerebral artery occlusion/reperfusion (MCAO/R) mouse model was used to replicate the CIRI model, low (0.5 mg/kg), medium (1 mg/kg) and high (2 mg/kg) concentrations of leptin were injected intraperitoneally immediately after inserting the embolic line. After 1.5 h of ischemia and 24 h of reperfusion, we examined the neural function of the mice, collected brain tissue for histological examination, and screened for the optimal concentrations of leptin intervention. On this basis, we observed the changes of cortical apoptosis injury, intracellular calcium fluorescence intensity and astrocyte glial fibrillary acidic protein (GFAP) expression and morphological changes. In addition, we also tested the expression of transporters and metabolism-related enzymes (VGLUT-1, VGLUT-2, GLAST, GLT-1, GS, ATP1α1), the expression of inflammatory factors and the content of glutamate (Glu). Compared with the I/R group, we found that leptin improved neurological deficits, reduced the area of infarcts, maintained the normal morphology of astrocytes (AST), downregulated the expression of VGLUT-1, and upregulates the expression of GLT-1 and GLAST, thereby reducing the content of Glu in the synaptic cleft. Our studies suggest that leptin may have a neuroprotective effect by decreasing the excitotoxicity of glutamate.